Pfizer Aims to Tackle Obesity with New Daily Danuglipron Medication

Pfizer announced early Thursday morning that it has chosen its preferred once-daily modified release formulation of danuglipron, marking a significant milestone in the development of its obesity drug.

Danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, will undergo dose optimisation studies in the latter half of 2024. Pfizer aims to evaluate multiple doses of this formulation, which they hope will inform the registration-enabling studies.

“Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates. The most advanced of them, danuglipron, has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space,” said Mikael Dolsten, MD., PhD., chief scientific officer & president, Pfizer Research and Development.